Effects of different genders on the ED50 of anesthesia-induced remimazolam and differences in electroencephalographic characteristics in patients undergoing day surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079965

Enrollment

Unknown

Registered

2024-01-17

Start date

2024-01-18

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing day surgery

Interventions

Male group(M group):Male: Remimazolam 0.25 mg/kg

Female group(F group):Female: Remimazolam 0.25 mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Patients undergoing elective day surgery, ASAI-III; 2) Age 18-65 years; 3) BMI 18.5-28 kg/m²; 4) No significant cardiopulmonary disease; 5) Normal communication; 6) Voluntary and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe respiratory and circulatory system diseases; 2. Neurological disorders; 3. Mental and psychological diseases; 4. Long-term drug abuse; 5. Complicated with obvious abnormal liver and kidney function; 6. Possible difficult airway; 7. People who are allergic to remimazolam and other narcotic drugs.

Design outcomes

Primary

Measure	Time frame
Median effective dose of remimazolam ;	—

Secondary

Measure	Time frame
Hemodynamic Indicators;time index;	—

Countries

China

Contacts

Public ContactTang Lili

The First Affiliated Hospital of Anhui Medical University

tanglilys@163.com+86 186 5411 0160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026